Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Upgraded to Buy at DNB Markets

DNB Markets upgraded shares of Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVFGet Rating) from a hold rating to a buy rating in a research report sent to investors on Thursday, The Fly reports.

BIOVF has been the subject of a number of other reports. Barclays lifted their price objective on Swedish Orphan Biovitrum AB (publ) from SEK 210 to SEK 215 in a research note on Tuesday, February 22nd. Nordea Equity Research raised Swedish Orphan Biovitrum AB (publ) from a hold rating to a buy rating in a research note on Friday, February 11th. Finally, Zacks Investment Research cut Swedish Orphan Biovitrum AB (publ) from a strong-buy rating to a hold rating in a research note on Monday, February 21st. Five investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of Hold and a consensus price target of $118.50.

BIOVF stock opened at $24.18 on Thursday. The company has a market cap of $7.25 billion, a P/E ratio of 20.84 and a beta of 0.45. Swedish Orphan Biovitrum AB has a twelve month low of $15.13 and a twelve month high of $28.88. The company has a quick ratio of 0.53, a current ratio of 0.93 and a debt-to-equity ratio of 0.43. The business has a fifty day moving average of $21.57 and a 200-day moving average of $22.61.

Swedish Orphan Biovitrum AB (publ) Company Profile (Get Rating)

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.

Further Reading

The Fly logo

Analyst Recommendations for Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF)

Receive News & Ratings for Swedish Orphan Biovitrum AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Swedish Orphan Biovitrum AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.